European Respiratory Society

Investigators increasingly view the disease as the result of different lifetime lung function trajectories, including cases where lungs never reach expected peak capacity during childhood, a framing consistent with the broader toll fine particulate matter already takes on children's developing lungs.

ERS Advocacy Council Chair Barbara Hoffman linked the research to a 2022 Lancet Commission argument that COPD is shaped by risk pathways across a person's life, not solely adult smoking, adding that air pollution, unlike genetic risk, can actually be addressed through policy.

The study carries real limitations.

Different lung function tests for newborns and six-year-olds required statistical alignment, and the genetic risk score was built largely from populations of European ancestry, so results may not translate equally elsewhere.

Tomorrow, Roivant and Pulmavant present focus results for Moslesiguat in pulmonary hypertension associated with interstitial lung disease.

The European Respiratory Society presentation is at 6.15 a.m. Eastern, followed by an investor call at 8.00.

The primary endpoint measures resistance to blood flow through the lung vessels at 16 weeks.

I'll read it alongside walking distance and safety.

He graduated from the National University of Ireland in Galway in 1993 and completed his specialist training in respiratory medicine and general internal medicine across university teaching hospitals in Dublin.

He later undertook a European Respiratory Society fellowship at the National Heart and Lung Institute at the Royal Brompton Hospital in London.

and was awarded his doctorate in medicine from the National University of Ireland in 2002.

Professor Maloney has held consultant positions in both Ireland and the UK, including in Sheffield University Teaching Hospital, before returning to Dublin in 2007.

He's played an active role in shaping respiratory and sleep medicine nationally and internationally, including serving as president of the Irish Sleep Society, council member and now president of the Irish Thoracic Society, and Ireland's national delegate to the European Respiratory Society.

He's also contributed extensively to medical education, training and healthcare leadership through roles with the Royal College of Physicians of Ireland, Tally University Hospital and Piedmont Healthcare.

He's contributed widely to respiratory medicine through research, publications and international presentations.

It was up about fifteen or twenty percent at one point in time.

And news came out that, uh, uh, an abstract that was to be presented at, uh, the European Respiratory Society meeting, ERS, was, was available.

A few of our investor clients had access to it.

Um, the data in the abstract were honestly not that remarkable.

Patients were followed up for all-cause death for a median of 3.7 years.

These echocardiographic phenotypes were present in all European Society of Cardiology stroke European Respiratory Society or Reveal 2.0 risk groups except for the high risk groups which included only phenotype 3 and phenotype 4 In each risk group RV phenotype 4 identified patients with a poorer prognosis RV phenotype 1 identified patients with better survival in intermediate risk groups.

The authors conclude that echocardiography derived phenotypes describing different degrees of RV remodeling and dysfunction provide prognostic information which is independent of and additional to the clinically defined risk in PAH patients at first follow-up.

The manuscript is accompanied by an editorial by Stanislav Henkin and Gregory Piazza from Mayo Clinic in Rochester, Minnesota, USA and Harvard Medical School in Boston, Massachusetts, USA.

That's easiest insofar as it is an exclusion from the guidelines.

All the major respiratory guidelines now for pneumonia, so the European Respiratory Society guidelines, the American Thoracic Society guidelines, NICE and BTS, regard VAP as enough of a separate entity that they're excluded from their HAP and CAP guidance.

So VAP being a pneumonia that occurs 48 hours or more after an episode of ventilation.

CAP is someone who presents with a syndrome of lower respiratory tract infection and in hospital has a new lung infiltrate who has not been recently in hospital.

So there was a period of time where major international respiratory guidelines were invoking another syndrome called healthcare-associated pneumonia.

And that would encompass the patients that you are talking about, so patients who present to hospital with pneumonia but present from healthcare institutions such as a nursing home.

Probably around 2017, when the last European Respiratory Society guidance came out, they explicitly removed that terminology because the evidence is showing that people who present to hospital from a nursing home with a pneumonia... their spectrum of pathogens is more similar to community acquired pneumonia than was previously thought and so I suppose if there's a take home for this audience is that there are really now three clinical syndromes that we should be talking about in terms of our practical management and that is VAP, HAP and CAP and that That old entity of healthcare-associated pneumonia has gone.

So finally, if you come to hospital from a nursing home and you've got pneumonia, unless you've been recently discharged, you've got CAP.